cbdMD (YCBD) Stock Forecast, Price & News

cbdMD (NYSEAMERICAN:YCBD) Frequently Asked Questions

Is cbdMD a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for cbdMD in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" cbdMD stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in YCBD, but not buy additional shares or sell existing shares.
View analyst ratings for cbdMD or view top-rated stocks.

When is cbdMD's next earnings date?

cbdMD is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for cbdMD.

How were cbdMD's earnings last quarter?

cbdMD, Inc. (NYSEAMERICAN:YCBD) released its quarterly earnings results on Thursday, December, 16th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.03. The firm had revenue of $9.79 million for the quarter. cbdMD had a negative trailing twelve-month return on equity of 9.28% and a negative net margin of 64.39%.
View cbdMD's earnings history.

What price target have analysts set for YCBD?

1 equities research analysts have issued 12 month price targets for cbdMD's shares. Their forecasts range from $3.25 to $3.25. On average, they anticipate cbdMD's share price to reach $3.25 in the next twelve months. This suggests a possible upside of 364.3% from the stock's current price.
View analysts' price targets for cbdMD or view top-rated stocks among Wall Street analysts.

Who are cbdMD's key executives?

cbdMD's management team includes the following people:

• Mr. Martin A. Sumichrast, Chairman & Co-CEO (Age 55, Pay $590.18k)
• Mr. Raymond Scott Coffman, Co-Founder, Pres, Co-CEO & Director (Age 60, Pay $563.29k)
• Mr. T. Ronan Kennedy, CFO, COO, Sec. & Treasurer (Age 42, Pay $247.12k)
• Mr. John Weston, Director of Investor Relations
• Mr. Lance Blundell, Gen. Counsel (Age 51)
• Robert Pettway, Director of PR
• Mr. Francisco Mangual, Sr. VP of Sales (Age 43)
• Mr. Matthew Coapman, Chief Marketing Officer (Age 46)
• Dr. Sibyl Swift Ph.D., VP for Scientific & Regulatory Affairs (Age 41)
• Mr. David Johnson, Sr. VP of Bus. Devel. (Age 52)

Who are some of cbdMD's key competitors?

Some companies that are related to cbdMD include Waldencast Acquisition (WALD), United-Guardian (UG), NuGene International (NUGN), CCA Industries (CAWW), Stephan (SPCO), Global Digital Solutions (GDSI), FOMO (ETFM), Lee Pharmaceuticals (LPHM), DS Healthcare Group (DSKX), Ascendia Brands (ASCBQ), Human Pheromone Sciences (EROX) and Nextera Enterprises (NXRA).
View all of YCBD's competitors.

What other stocks do shareholders of cbdMD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other cbdMD investors own include KushCo (KSHB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Novan (NOVN), Bionano Genomics (BNGO), CNBX Pharmaceuticals (CNBX), Enerplus (ERF), Matinas BioPharma (MTNB), OrganiGram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).

What is cbdMD's stock symbol?

cbdMD trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "YCBD."

Who are cbdMD's major shareholders?

cbdMD's stock is owned by many different retail and institutional investors. Top institutional shareholders include Mirae Asset Global Investments Co. Ltd. (2.16%), Vanguard Group Inc. (1.98%), AdvisorShares Investments LLC (1.71%), Penserra Capital Management LLC (0.85%), Anchor Capital Advisors LLC (0.25%) and Davy Global Fund Management Ltd (0.22%). Company insiders that own cbdMD stock include Bakari T Sellers, Martin A Sumichrast, Raymond Scott Coffman, Thomas Ronan Kennedy and William F Raines III.
View institutional ownership trends for cbdMD.

Which institutional investors are selling cbdMD stock?

YCBD stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Penserra Capital Management LLC, Mirae Asset Global Investments Co. Ltd., swisspartners Ltd., AdvisorShares Investments LLC, Group One Trading L.P., and Simplex Trading LLC.
View insider buying and selling activity for cbdMD or view top insider-selling stocks.

Which institutional investors are buying cbdMD stock?

YCBD stock was acquired by a variety of institutional investors in the last quarter, including Davy Global Fund Management Ltd, Anchor Capital Advisors LLC, Vident Investment Advisory LLC, and Renaissance Technologies LLC.
View insider buying and selling activity for cbdMD or or view top insider-buying stocks.

How do I buy shares of cbdMD?

Shares of YCBD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is cbdMD's stock price today?

One share of YCBD stock can currently be purchased for approximately $0.70.

How much money does cbdMD make?

cbdMD has a market capitalization of $41.55 million and generates $44.48 million in revenue each year. The company earns $-23.40 million in net income (profit) each year or ($0.47) on an earnings per share basis.

How many employees does cbdMD have?

cbdMD employs 154 workers across the globe.

What is cbdMD's official website?

The official website for cbdMD is www.cbdmd.com.

How can I contact cbdMD?

cbdMD's mailing address is 8845 Red Oak Boulevard, Charlotte NC, 28217. The company can be reached via phone at (704) 445-3060 or via email at [email protected].